National Health (Pharmaceuticals and Vaccines—Cost Recovery) Regulations 2022
71Reviewable decisions
Start here
Get a plain-English read of 71
Turn the raw legal text into a practical explanation grounded in National Health (Pharmaceuticals and Vaccines—Cost Recovery) Regulations 2022.
71 Reviewable decisions
This Part applies to the following decisions (reviewable decisions) of the Secretary: (a) a decision under subsection 8(1) that an ATAGI application is not in a simple category; (b) a refusal under subsection 9(3) to decide that a notice of intent in relation to a proposed ATAGI application is not required; (c) a refusal under subsection 30(3) to decide that a notice of intent in relation to a proposed submission is not required; (d) a decision under subsection 37(1) determining the evaluation category that a submission is in; (e) a refusal under subsection 48(3) to decide that a notice of intent in relation to a proposed pricing application is not required; (f) a decision under subsection 52(1) determining the pricing category that a pricing application is in; (g) a decision under subsection 65(2) not to refund a fee; (h) a decision under subsection 65(3) not to remit a fee; (i) a decision under subsection 68(1) or 69(1) not to waive a fee that is payable; (j) a decision under subsection 74(2) (about decisions made on reviews initiated by the Secretary).
Note: The decision could be made by a delegate of the Secretary (see subsection 6(5) of the Act).